Thymidylate-synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis

Journal of Clinical Oncology

Volumn 22, Issue 3, 2004, Pages 529-536

  Popat, Sanjay ^a   Matakidou, Athena ^a   Houlston, Richard S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

THYMIDYLATE SYNTHASE;

CANCER SURVIVAL; CELL HETEROGENEITY; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; META ANALYSIS; METHODOLOGY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; ENZYMOLOGY; METABOLISM; MORTALITY; SURVIVAL RATE; TREATMENT OUTCOME;

COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; PROGNOSIS; SURVIVAL RATE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 1442290323     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.064     Document Type: Review

References (54)

1. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594-606, 1993
2. Finlay IG, Pickford IR: Colorectal carcinoma, in Lawson DH (ed): Current Medicine 4th edition, Ediburgh, Churchill Livingstone, 1994, pp 51-64
3. Anonymous: NIH consensus conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
4. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122: 321-326, 1995
5. Mamounas E, Wieand S, Wolmark N, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17: 1349-1355, 1999
6. Danenberg PV, Langenbach RJ, Heidelberger C: Structures of reversible and irreversible complexes of thymidylate synthetase and fluorinated pyrimidine nucleotides. Biochemistry 13:926-933, 1974
7. Kufe DW, Major PP, Egan EM, et al: 5-Fluoro-2′-deoxyuridine incorporation in L1210 DNA. J Biol Chem 256:8885-8888, 1981
8. Danenberg PV, Heidelberger C, Mulkins MA, et al: The incorporation of 5-fluoro-2′-deoxyuridine into DNA of mammalian tumor cells. Biochem Biophys Res Commun 102:654-658, 1931
9. Santi DV, McHenry CS, Sommer H: Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13:471-481, 1974
10. Berger SH, Jenh CH, Johnson LF, et al: Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 28:461-467, 1985
11. Johnston PG, Drake JC, Trepel J, et al: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52:4306-4312, 1992
12. Kleinbaum DG, Krupper LL, Morgenstern H: Epidemiologic research. New York, NY, Van Nostrand Reinhold Co, 1982, pp359
13. Leichman CG, Lenz HJ, Leichman L: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223-3229, 1997
14. Lenz HJ, Danenberg KD, Leichman CG, et al: p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site. Clin Cancer Res 4:1227-1234, 1998
15. Lenz HJ, Hayashi K, Salonga D, et al: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival. Clin Cancer Res 4:1243-1250, 1998
16. Davies MM, Johnston PG, Kaur S, et al: Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin Cancer Res 5:325-328, 1999
17. Bathe OF, Franceschi D, Livingstone AS, et al: Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: Implications for chemotherapeutic options and survival. Cancer J Sci Am 5:34-40, 1999
18. Takenoue T, Nagawa H, Matsuda K, et al: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 7:193-198, 2000
19. Tomiak A, Vincent M, Earle CC, et al: Thymidylate synthase expression in stage II and III colon cancer: A retrospective review. Am J Clin Oncol 24:597-602, 2001
20. Allegra CJ, Parr AL, Wold LE, et al: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20:1735-1743, 2002
21. Nanni O, Volpi A, Frassineti GL, et al: Role of biological markers in the clinical outcome of colon cancer. Br J Cancer 87:868-875, 2002
22. Berglund A, Edler D, Molin D, et al: Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma. Anticancer Res 22:3653-3659, 2002
23. Gonen M, Hummer A, Zervoudakis A, et al: Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 21:406-412, 2003
24. Ichikawa W, Uetake H, Shirota Y, et al: Combination of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Gene Expressions in Primary Tumors as Predictive Parameters for the Efficacy of Fluoropyrimidine-based Chemotherapy for Metastatic Colorectal Cancer. Clin Cancer Res 9:786-791, 2003
25. Farrugia DC, Ford HE, Cunningham D, et al: Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res 9:792-801, 2003
26. Johnston PG, Benson AB III, Catalano P, et al: Thymidylate synthase protein expression in primary colorectal cancer: Lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 21:815-819, 2003
27. Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med 17:2815-2834, 1998
28. Mitsudomi T, Hamajima N, Ogawa M, et al: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis. Clin Cancer Res 6:4055-4063, 2000
29. Edler D, Glimelius B, Hallstrom M, et al: Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20:1721-1728, 2002
30. Pharoah PD, Day NE, Caldas C: Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis. Br J Cancer 80:1968-1973, 1999
31. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin trials 7:177-178, 1986
32. Egger M, Smith GD, Schneider M, et al: Bias in meta-analysis detected by a simple graphical test. BMJ 315:629-634, 1997
33. Sharpe S, Sterne J: META. Stata Technical Bulletin 38. Stata Corporation, 1998
34. Edler D, Kressner U, Ragnhammar P, et al: Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival. Clin Cancer Res 6:488-492, 2000
35. Mini E, Biondi C, Morganti M, et al: Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. Oncol Res 11:437-445, 1999
36. Findlay MP, Cunningham D, Morgan G, et al: Lack of correlation between thymidylate synthase levels in primary colorectal tumors and subsequent response to chemotherapy. Br J Cancer 75:903-909, 1997
37. Link KH, Kornmann M, Butzer U, et al: Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy. Cancer 89:288-296, 2000
38. van Triest B, Pinedo HM, Blaauwgeers JL, et al: Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 6:1063-1072, 2000
39. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640-2647, 1994
40. Sanguedolce R, Vultaggio G, Sanguedolce F, et al: The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res 18:1515-1520, 1998
41. Tachikawa D, Arima S, Futami K: Immunohistochemical expression of thymidylate synthase as a prognostic factor and as a chemotherapeutic efficacy index in patients with colorectal carcinoma. Anticancer Res 20:4103-4107, 2000
42. Edler D, Hallstrom M, Johnston PG, et al: Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 6:1378-1384, 2000b
43. Yamachika T, Nakanishi H, Inada K, et al: A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82:70-77, 1998
44. Allegra CJ, Paik S, Colangelo LH, et al: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21:241-250, 2003
45. Aschele C, Debernardis D, Casazza S, et al: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17: 1760-1770, 1999
46. Paradiso A, Simone G, Petroni S, et al: Thymidylate synthase and p53 primary tumor expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82:560-567, 2000
47. Shirota Y, Stoehlmacher J, Brabender J, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298-4304, 2001
48. Etienne MC, Chazal M, Laurent-Puig P, et al: Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: Phenotypic and genotypic analyses. J Clin Oncol 20:2832-2843, 2002
49. Kornmann M, Link KH, Galuba I, et al: Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer. J Gastrointest Surg 6:331-337, 2002
50. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327, 2000
51. Kawakami K, Omura K, Kanehira E, et al: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19:3249-3252, 1999
52. Aschele C, Debernardis D, Tunesi G, et al: Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6:4797-4802, 2000
53. Sacks HS, Berrier J, Reitman D, et al: Meta-analyses of randomized controlled trials. N Engl J Med 316:450-455, 1987
54. Dickersin K, Berlin JA: Meta-analysis: State-of-the-science. Epidemiol Rev 14:154-176, 1992